Abstract
Keywords
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Breast CancerReferences
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.N Engl J Med. 2020; 382: 597-609https://doi.org/10.1056/nejmoa1914609
- From improved survival to potential cure in patients with metastatic breast cancer Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review.Breast Cancer. 2012; 19: 218-237https://doi.org/10.1007/s12282-012-0347-0
- The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer.Cancer. 2007; 110: 973-979https://doi.org/10.1002/cncr.22867
- Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science (80-). 1987; 235: 182-191https://doi.org/10.1126/science.3798106
- Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N Engl J Med. 2001; 344: 783-792https://doi.org/10.1056/nejm200103153441101
- Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review.J Clin Oncol. 2010; 28: 92-98https://doi.org/10.1200/JCO.2008.19.9844
- Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy.JNCCN J Natl Compr Cancer Netw. 2014; 12: 71-80https://doi.org/10.6004/jnccn.2014.0008
- Divergent evolution of overall survival across metastatic breast cancer (MBC) subtypes in the nationwide ESME real life cohort 2008-2016.Ann Oncol. 2020; 31: S352-S353https://doi.org/10.1016/j.annonc.2020.08.380
- Pertuzumab plus Trastuzumab plus Docetaxel for metastatic breast cancer.N Engl J Med. 2012; 366: 109-119https://doi.org/10.1056/nejmoa1113216
- Breast surgery for metastatic breast cancer.Cochrane Database Syst Rev. 2018; 2018https://doi.org/10.1002/14651858.CD011276.pub2
- Long-Term Survival of De Novo stage IV human epidermal growth receptor 2 (HER2) positive breast cancers treated with HER2-targeted therapy.Oncologist. 2019; 24: 313-318https://doi.org/10.1634/theoncologist.2018-0213
- Surgical management of de novo Stage IV breast cancer.Semin Radiat Oncol. 2016; 26: 79-86https://doi.org/10.1016/j.semradonc.2015.08.004
- Cancer statistics, 2020.CA Cancer J Clin. 2020; 70: 7-30https://doi.org/10.3322/caac.21590
- Adjuvant Trastuzumab in HER2-positive breast cancer.N Engl J Med. 2011; 365: 1273-1283https://doi.org/10.1056/NEJMoa0910383
- Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 - Positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.J Clin Oncol. 2014; 32: 3744-3752https://doi.org/10.1200/JCO.2014.55.5730
- Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.N Engl J Med. 2005; 353: 1659-1672https://doi.org/10.1056/nejmoa052306
- De Novo Versus Recurrent HER2-positive metastatic breast cancer: patient characteristics, treatment, and survival from the SystHERs registry.Oncologist. 2020; 25https://doi.org/10.1634/theoncologist.2019-0446
- Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER.Br J Cancer. 2014; 110: 2756-2764https://doi.org/10.1038/bjc.2014.174
- Patterns of care and clinical outcomes of HER2-positive Metastatic breast cancer patients with newly diagnosed stage IV or recurrent disease undergoing first-line trastuzumab-based therapy: a multicenter retrospective cohort study.Clin Breast Cancer. 2017; 17 (e2): 601-610https://doi.org/10.1016/j.clbc.2017.04.002
- Survival with metastatic breast cancer based on initial presentation, de novo vs. relapsed.Breast Cancer Res Treat. 2017; 161: 549-556https://doi.org/10.1007/s10549-016-4080-9
- Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?.Br J Cancer. 2015; 112: 1445-1451https://doi.org/10.1038/bjc.2015.127
- Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer.Cancer. 2014; 120: 1932-1938https://doi.org/10.1002/cncr.28689
- Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.Breast. 2014; 23: 44-49https://doi.org/10.1016/j.breast.2013.10.005
- Is breast cancer survival improving?.Cancer. 2004; 100: 44-52https://doi.org/10.1002/cncr.11859
- Can we cure limited metastatic breast cancer?.J Clin Oncol. 2002; 20: 620-623https://doi.org/10.1200/JCO.2002.20.3.620
- Distant metastatic breast cancer as an incurable disease: a tenet with a need for revision.Cancer J. 2009; 15: 81-86https://doi.org/10.1097/PPO.0b013e31818d8509
- International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?.J Natl Cancer Inst. 2010; 102: 456-463https://doi.org/10.1093/jnci/djq029
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-positive metastatic breast cancer A BS TR AC T.N Engl J Med. 2015; 372: 724-758https://doi.org/10.1056/NEJMoa1413513
- Circulating tumor cells in breast cancer.Mol Oncol. 2016; 10: 418-430https://doi.org/10.1016/j.molonc.2016.01.001
- Analysis of circulating tumor DNA to monitor metastatic breast cancer A bs tr ac t.NEJM.org. 2013; 368: 1199-1209https://doi.org/10.1056/NEJMoa1213261
- A role for curative surgery in the treatment of selected patients with metastatic breast cancer.Oncologist. 2003; 8: 241-251https://doi.org/10.1634/theoncologist.8-3-241
- Comparative analysis of durable responses on immune checkpoint inhibitors vs. other systemic therapies: a pooled analysis of phase III trials.JCO Precis Oncol. 2019; : 1-10https://doi.org/10.1200/PO.18.00114
- A clinical feasibility trial for identification of exceptional responders in whom breast cancer surgery can be eliminated following neoadjuvant systemic therapy.Ann Surg. 2018; 267: 946-951https://doi.org/10.1097/SLA.0000000000002313
- Can maintenance trastuzumab be stopped in patients with HER2-positive metastatic breast cancer?.BMJ Case Rep. 2015; 2015https://doi.org/10.1136/bcr-2014-207750
- Complete remission in metastatic breast cancer: expecting the unexpected—results of a cross-sectional study.Breast Cancer. 2017; 24: 635-641https://doi.org/10.1007/s12282-017-0751-6
- Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis.Breast Cancer Res Treat. 2018; 167: 81-87https://doi.org/10.1007/s10549-017-4489-9
- Metastatic HER2+ breast cancer: a potentially curable disease?.Cureus. 2017; 9https://doi.org/10.7759/cureus.1654
- Durable complete response following chemotherapy and trastuzumab for metastatic her2-positive breast cancer.Ann Oncol. 2012; 23: 2204-2205https://doi.org/10.1093/annonc/mds221
Steenbruggen TG, Bouwer N I, Smorenburg C H, et al. Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab? 2019;178:597-605. doi:10.1007/s10549-019-05427-1
Ihnenfeld Arciénega I, Imesch P, Fink D, Dedes KJ. Prolonged complete remission of metastatic HER2-positive breast cancer after continuous trastuzumab treatment: a case report and review of the literature. doi:10.1007/s11523-014-0350-9
Giordano SH, Temin S, Kirshner JJ, et al. Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Published online 2014. doi:10.1200/JCO.2013.54.0948
- Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer.Breast Cancer Res Treat. 2016; 159: 367-374https://doi.org/10.1007/s10549-016-3933-6
- Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer - results from the HER-OS patient registry.BMC Cancer. 2014; 14https://doi.org/10.1186/1471-2407-14-806
- Long-term follow-up of patients with metastatic breast cancer treated by trastuzumab: impact of institutions.Breast. 2014; 23: 165-169https://doi.org/10.1016/j.breast.2013.12.003
- Adenocarcinoma of the kidney with metastasis to the lung: cured by nephrectomy and lobectomy1.J Urol. 1939; 42: 269-276https://doi.org/10.1016/S0022-5347(17)71516-9
- Safety and survival rates associated with ablative stereotactic radiotherapy for patients with oligometastatic cancer: a systematic review and meta-analysis.JAMA Oncol. 2020; 7: 92-106https://doi.org/10.1001/jamaoncol.2020.6146
- Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET Phase II randomized trial.J Clin Oncol. 2020; 38: 2830-2838https://doi.org/10.1200/JCO.20.00818
Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E, Group W. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up †. Published online 2012. doi:10.1093/annonc/mds232.
- A randomized phase III trial of systemic therapy plus early local therapy vs. systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108).J Clin Oncol. 2020; 38 (LBA2-LBA2)https://doi.org/10.1200/JCO.2020.38.18_suppl.LBA2
- T-DM1 activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with Trastuzumab and Pertuzumab.J Clin Oncol. 2016; 34: 3511-3517https://doi.org/10.1200/JCO.2016.67.3624
- Long-Term Outcome of Patients (Pts) with Her2-Positive (Her2+) Metastatic Breast Cancer (Mbc) Who Achieved a Complete Response (Cr) After Antiher2 Therapy (Her2Tx).Ann Oncol. 2014; 25: iv124https://doi.org/10.1093/annonc/mdu329.25